Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Rapid decrease in age-adjusted mortality rates associated with ITP following eltrombopag aand romiplostin approvals, but not in TMA following eculizumab approval, 1999-2023

View Full Paper
Ask AI
Bookmark
Share

Authors

EZEli Zolotov

Discussion

Loading...

Member takes

Overview

Analysis shows significant decline in age-adjusted mortality rates for ITP post-eltrombopag approval, suggesting effective treatment.

Key Points

  • Age-adjusted mortality rates for ITP decreased significantly to 0.39 per million post-eltrombopag approval.
  • The AAMR for TMA showed a decline but lacked significant change post-eculizumab approval with AAMR at 0.64.
  • Analysis using CDC WONDER database examined mortality trends for ITP and TMA using defined ICD codes.
  • Findings imply that the introduction of eltrombopag and romiplostim has had a strong positive effect on ITP outcomes.

Cite This Study

Eli Zolotov (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236e008https://doi.org/10.1182/blood-2025-4467
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Thrombotic thrombocytopenic purpura-related mortality trends among the United States population: A retrospective study using the CDC wonder database2025
  2. 2Trends and disparities in immune thrombocytopenic purpura-related mortality in the United States: a retrospective study over 24 years2025
  3. 3Ethnic, racial, and geographic disparities in idiopathic thrombocytopenic purpura related mortality along the US-Mexico border from 1999 to 20202025
  4. 4The unseen bleed- temporal and demographic patterns of thrombocytopenia mortality in the United States: A 25-year analysis of the CDC wonder database2025
  5. 5Trends in thromboembolism-related mortality among patients with hematologic malignancies in the u.S., 1999–2023: A CDC wonder analysis2025 · 1 citations